Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL BLOOD PLASMA MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL BLOOD PLASMA MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL BLOOD PLASMA MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6 INDUSTRY INSIGHTS
6.1 MICRO AND MACRO ECONOMIC FACTORS
6.2 PENETRATION AND GROWTH PROSPECT MAPPING
6.3 KEY PRICING STRATEGIES
6.4 INTERVIEWS WITH SPECIALIST
6.5 ANALYIS AND RECOMMENDATION
7 INTELLECTUAL PROPERTY (IP) PORTFOLIO
7.1 PATENT QUALITY AND STRENGTH
7.2 PATENT FAMILIES
7.3 LICENSING AND COLLABORATIONS
7.4 COMPETITIVE LANDSCAPE
7.5 IP STRATEGY AND MANAGEMENT
7.6 OTHER
8 COST ANALYSIS BREAKDOWN
9 TECHNONLOGY ROADMAP
10 INNOVATION TRACKER AND STRATEGIC ANALYSIS
10.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS
10.1.1 JOINT VENTURES
10.1.2 MERGERS AND ACQUISITIONS
10.1.3 LICENSING AND PARTNERSHIP
10.1.4 TECHNOLOGY COLLABORATIONS
10.1.5 STRATEGIC DIVESTMENTS
10.2 NUMBER OF PRODUCTS IN DEVELOPMENT
10.3 STAGE OF DEVELOPMENT
10.4 TIMELINES AND MILESTONES
10.5 INNOVATION STRATEGIES AND METHODOLOGIES
10.6 RISK ASSESSMENT AND MITIGATION
10.7 MERGERS AND ACQUISITIONS
10.8 FUTURE OUTLOOK
11 EPIDEMIOLOGY
11.1 INCIDENCE OF ALL BY GENDER
11.2 TREATMENT RATE
11.3 MORTALITY RATE
11.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
11.5 PATIENT TREATMENT SUCCESS RATES
12 REGULATORY COMPLIANCE
12.1 REGULATORY AUTHORITIES
12.2 REGULATORY CLASSIFICATIONS
12.2.1 CLASS I
12.2.2 CLASS II
12.2.3 CLASS III
12.3 REGULATORY SUBMISSIONS
12.4 INTERNATIONAL HARMONIZATION
12.5 COMPLIANCE AND QUALITY MANAGEMENT SYSTEMS
12.6 REGULATORY CHALLENGES AND STRATEGIES
13 PIPELINE ANALYSIS
13.1 CLINICAL TRIALS AND PHASE ANALYSIS
13.2 DRUG THERAPY PIPELINE
13.3 PHASE III CANDIDATES
13.4 PHASE II CANDIDATES
13.5 PHASE I CANDIDATES
13.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR BLOOD PLASMA MARKET
Company Name Product Name
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE FOR BLOOD PLASMA MARKET
Phase Number of Projects
Preclinical/Research Projects XX
Clinical Development XX
Phase I XX
Phase II XX
Phase III XX
U.S. Filed/Approved but Not Yet Marketed XX
Total XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE FOR BLOOD PLASMA MARKET
Therapeutic Area Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE FOR BLOOD PLASMA MARKET
Technology Preclinical/ Research Project
XX XX
XX XX
XX XX
XX XX
XX XX
Total Projects XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR BLOOD PLASMA MARKET
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
14 REIMBURSEMENT FRAMEWORK
15 OPPUTUNITY MAP ANALYSIS
16 VALUE CHAIN ANALYSIS
17 HEALTHCARE ECONOMY
17.1 HEALTHCARE EXPENDITURE
17.2 CAPITAL EXPENDITURE
17.3 CAPEX TRENDS
17.4 CAPEX ALLOCATION
17.5 FUNDING SOURCES
17.6 INDUSTRY BENCHMARKS
17.7 GDP RATION IN OVERALL GDP
17.8 HEALTHCARE SYSTEM STRUCTURE
17.9 GOVERNMENT POLICIES
18 GLOBAL BLOOD PLASMA MARKET, BY PRODUCT
18.1 OVERVIEW
18.2 IMMUNOGLOBULINS
18.2.1 BY TYPE
18.2.1.1. INTRAVENOUS IMMUNOGLOBULINS
18.2.1.2. SUBCUTANEOUS IMMUNOGLOBULINS
18.2.1.3. OTHER IMMUNOGLOBULINS
18.2.2 BY APPLICATION
18.2.2.1. NEUROLOGY
18.2.2.1.1. MYASTHENIA GRAVIS
18.2.2.1.2. GUILLAIN-BARRÉ SYNDROME
18.2.2.1.3. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
18.2.2.1.4. OTHERS
18.2.2.2. IMMUNOLOGY
18.2.2.3. LUPUS
18.2.2.4. RHEUMATOID ARTHRITIS
18.2.2.5. SCLERODERMA
18.2.2.6. SJÖGREN'S SYNDROME
18.2.2.7. HEMATOLOGY
18.2.2.8. CRITICAL CARE
18.2.2.9. PULMONOLOGY
18.2.2.10. HEMATO-ONCOLOGY
18.2.2.11. RHEUMATOLOGY
18.2.2.12. OTHER APPLICATIONS
18.3 COAGULATION FACTOR CONCENTRATES
18.3.1 BT TYPE
18.3.1.1. FACTOR VIII
18.3.1.2. FACTOR IX
18.3.1.3. VON WILLEBRAND FACTOR
18.3.1.4. PROTHROMBIN COMPLEX CONCENTRATE
18.3.1.5. FIBRINOGEN CONCENTRATES
18.3.1.6. FACTOR XIII
18.3.2 BY APPLICATION
18.3.2.1. NEUROLOGY
18.3.2.1.1. MYASTHENIA GRAVIS
18.3.2.1.2. GUILLAIN-BARRÉ SYNDROME
18.3.2.1.3. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
18.3.2.1.4. OTHERS
18.3.2.2. IMMUNOLOGY
18.3.2.3. LUPUS
18.3.2.4. RHEUMATOID ARTHRITIS
18.3.2.5. SCLERODERMA
18.3.2.6. SJÖGREN'S SYNDROME
18.3.2.7. HEMATOLOGY
18.3.2.8. CRITICAL CARE
18.3.2.9. PULMONOLOGY
18.3.2.10. HEMATO-ONCOLOGY
18.3.2.11. RHEUMATOLOGY
18.3.2.12. OTHER APPLICATIONS
18.4 ALBUMIN
18.4.1 BY TYPE
18.4.1.1. HUMAN SERUM ALBUMIN
18.4.1.2. RECOMBINANT ALBUMIN
18.4.1.3. IV ALBUMIN
18.4.2 BY APPLICATION
18.4.2.1. NEUROLOGY
18.4.2.1.1. MYASTHENIA GRAVIS
18.4.2.1.2. GUILLAIN-BARRÉ SYNDROME
18.4.2.1.3. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
18.4.2.1.4. OTHERS
18.4.2.2. IMMUNOLOGY
18.4.2.3. LUPUS
18.4.2.4. RHEUMATOID ARTHRITIS
18.4.2.5. SCLERODERMA
18.4.2.6. SJÖGREN'S SYNDROME
18.4.2.7. HEMATOLOGY
18.4.2.8. CRITICAL CARE
18.4.2.9. PULMONOLOGY
18.4.2.10. HEMATO-ONCOLOGY
18.4.2.11. RHEUMATOLOGY
18.4.2.12. OTHER APPLICATIONS
18.5 HYPERIMMUNE GLOBINS
18.5.1 BY TYPE
18.5.1.1. HEPATITIS B IMMUNE GLOBULIN (HBIG)
18.5.1.2. CYTOMEGALOVIRUS IMMUNE GLOBULIN
18.5.1.3. VARICELLA-ZOSTER IMMUNE GLOBULIN
18.5.1.4. RHO(D) IMMUNE GLOBULIN
18.5.2 BY APPLICATION
18.5.2.1. NEUROLOGY
18.5.2.1.1. MYASTHENIA GRAVIS
18.5.2.1.2. GUILLAIN-BARRÉ SYNDROME
18.5.2.1.3. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
18.5.2.1.4. OTHERS
18.5.2.2. IMMUNOLOGY
18.5.2.3. LUPUS
18.5.2.4. RHEUMATOID ARTHRITIS
18.5.2.5. SCLERODERMA
18.5.2.6. SJÖGREN'S SYNDROME
18.5.2.7. HEMATOLOGY
18.5.2.8. CRITICAL CARE
18.5.2.9. PULMONOLOGY
18.5.2.10. HEMATO-ONCOLOGY
18.5.2.11. RHEUMATOLOGY
18.5.2.12. OTHER APPLICATIONS
18.6 PROTEASE INHIBITORS
18.6.1 BY TYPE
18.6.1.1. ALPHA-1 ANTITRYPSIN (AAT)
18.6.1.2. C1 ESTERASE INHIBITOR (C1-INH)
18.6.1.3. ANTITHROMBIN III
18.6.2 BY APPLICATION
18.6.2.1. NEUROLOGY
18.6.2.1.1. MYASTHENIA GRAVIS
18.6.2.1.2. GUILLAIN-BARRÉ SYNDROME
18.6.2.1.3. CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
18.6.2.1.4. OTHERS
18.6.2.2. IMMUNOLOGY
18.6.2.3. LUPUS
18.6.2.4. RHEUMATOID ARTHRITIS
18.6.2.5. SCLERODERMA
18.6.2.6. SJÖGREN'S SYNDROME
18.6.2.7. HEMATOLOGY
18.6.2.8. CRITICAL CARE
18.6.2.9. PULMONOLOGY
18.6.2.10. HEMATO-ONCOLOGY
18.6.2.11. RHEUMATOLOGY
18.6.2.12. OTHER APPLICATIONS
18.7 OTHER PRODUCTS
19 GLOBAL BLOOD PLASMA MARKET, BY APPLICATION
19.1 OVERVIEW
19.2 NEUROLOGY
19.2.1 MYASTHENIA GRAVIS
19.2.2 GUILLAIN-BARRÉ SYNDROME
19.2.3 CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
19.2.4 OTHERS
19.3 IMMUNOLOGY
19.4 LUPUS
19.5 RHEUMATOID ARTHRITIS
19.6 SCLERODERMA
19.7 SJÖGREN'S SYNDROME
19.8 HEMATOLOGY
19.9 CRITICAL CARE
19.1 PULMONOLOGY
19.11 HEMATO-ONCOLOGY
19.12 RHEUMATOLOGY
19.13 OTHER APPLICATIONS
20 GLOBAL BLOOD PLASMA MARKET, BY PROCESSING TECHNOLOGY
20.1 OVERVIEW
20.2 ION-EXCHANGE CHROMATOGRAPHY
20.3 AFIINITY CHROMATOGRAPHY
20.4 CRYOPRECIPITATION
20.5 ULTRAFILTRATION
20.6 MICROFILTRATION
21 GLOBAL BLOOD PLASMA MARKET, BY MODE
21.1 MODERN PLASMA FRACTIONATION
21.2 TRADITIONAL PLASMA FRACTIONATION
22 GLOBAL BLOOD PLASMA MARKET, BY AGE GROUP
22.1 OVERVIEW
22.2 PEDIATRIC
22.3 ADULT
22.4 GERIATRIC
23 GLOBAL BLOOD PLASMA MARKET, BY END USER
23.1 OVERVIEW
23.2 HOSPITALS & CLINICS
23.3 CLINICAL RESEARCH LABORATORIES
23.4 ACADEMIC INSTITUTES
23.5 OTHERS
24 GLOBAL BLOOD PLASMA MARKET, BY DISTRIBUTION CHANNEL
24.1 OVERVIEW
24.2 DIRECT TENDERS
24.3 THIRD PARTY DISTRIBUTION
24.4 OTHERS
25 GLOBAL BLOOD PLASMA MARKET, COMPANY LANDSCAPE
25.1 COMPANY SHARE ANALYSIS: GLOBAL
25.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
25.3 COMPANY SHARE ANALYSIS: EUROPE
25.4 COMPANY SHARE ANALYSIS: ASIA PACIFIC
25.5 MERGERS & ACQUISITIONS
25.6 NEW PRODUCT DEVELOPMENT & APPROVALS
25.7 EXPANSIONS
25.8 REGULATORY CHANGES
25.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
26 GLOBAL BLOOD PLASMA MARKET, SWOT AND DBMR ANALYSIS
27 GLOBAL BLOOD PLASMA MARKET, COMPANY PROFILE
27.1 BIOTEST AG
27.1.1 COMPANY OVERVIEW
27.1.2 REVENUE ANALYSIS
27.1.3 GEOGRAPHIC PRESENCE
27.1.4 PRODUCT PORTFOLIO
27.1.5 RECENT DEVELOPEMENTS
27.2 CSL
27.2.1 COMPANY OVERVIEW
27.2.2 REVENUE ANALYSIS
27.2.3 GEOGRAPHIC PRESENCE
27.2.4 PRODUCT PORTFOLIO
27.2.5 RECENT DEVELOPEMENTS
27.3 GC BIOPHARMA CORP
27.3.1 COMPANY OVERVIEW
27.3.2 REVENUE ANALYSIS
27.3.3 GEOGRAPHIC PRESENCE
27.3.4 PRODUCT PORTFOLIO
27.3.5 RECENT DEVELOPEMENTS
27.4 GRIFOILS
27.4.1 COMPANY OVERVIEW
27.4.2 REVENUE ANALYSIS
27.4.3 GEOGRAPHIC PRESENCE
27.4.4 PRODUCT PORTFOLIO
27.4.5 RECENT DEVELOPEMENTS
27.5 INTAS PHARMACEUTICALS LTD.
27.5.1 COMPANY OVERVIEW
27.5.2 REVENUE ANALYSIS
27.5.3 GEOGRAPHIC PRESENCE
27.5.4 PRODUCT PORTFOLIO
27.5.5 RECENT DEVELOPEMENTS
27.6 KEDRION S.P.A.
27.6.1 COMPANY OVERVIEW
27.6.2 REVENUE ANALYSIS
27.6.3 GEOGRAPHIC PRESENCE
27.6.4 PRODUCT PORTFOLIO
27.6.5 RECENT DEVELOPEMENTS
27.7 LFB
27.7.1 COMPANY OVERVIEW
27.7.2 REVENUE ANALYSIS
27.7.3 GEOGRAPHIC PRESENCE
27.7.4 PRODUCT PORTFOLIO
27.7.5 RECENT DEVELOPEMENTS
27.8 OCTAPHARMA AG
27.8.1 COMPANY OVERVIEW
27.8.2 REVENUE ANALYSIS
27.8.3 GEOGRAPHIC PRESENCE
27.8.4 PRODUCT PORTFOLIO
27.8.5 RECENT DEVELOPEMENTS
27.9 SANQUIN
27.9.1 COMPANY OVERVIEW
27.9.2 REVENUE ANALYSIS
27.9.3 GEOGRAPHIC PRESENCE
27.9.4 PRODUCT PORTFOLIO
27.9.5 RECENT DEVELOPEMENTS
27.1 TAKEDA PHARMACEUTICALS
27.10.1 COMPANY OVERVIEW
27.10.2 REVENUE ANALYSIS
27.10.3 GEOGRAPHIC PRESENCE
27.10.4 PRODUCT PORTFOLIO
27.10.5 RECENT DEVELOPEMENTS
27.11 ABBVIE, INC.
27.11.1 COMPANY OVERVIEW
27.11.2 REVENUE ANALYSIS
27.11.3 GEOGRAPHIC PRESENCE
27.11.4 PRODUCT PORTFOLIO
27.11.5 RECENT DEVELOPEMENTS
27.12 IPSEN PHARMA
27.12.1 COMPANY OVERVIEW
27.12.2 REVENUE ANALYSIS
27.12.3 GEOGRAPHIC PRESENCE
27.12.4 PRODUCT PORTFOLIO
27.12.5 RECENT DEVELOPEMENTS
27.13 SUN PHARMACEUTICALS INDUSTRIES, LTD.
27.13.1 COMPANY OVERVIEW
27.13.2 REVENUE ANALYSIS
27.13.3 GEOGRAPHIC PRESENCE
27.13.4 PRODUCT PORTFOLIO
27.13.5 RECENT DEVELOPEMENTS
27.14 PFIZER, INC.
27.14.1 COMPANY OVERVIEW
27.14.2 REVENUE ANALYSIS
27.14.3 GEOGRAPHIC PRESENCE
27.14.4 PRODUCT PORTFOLIO
27.14.5 RECENT DEVELOPEMENTS
27.15 EUROPLASMA
27.15.1 COMPANY OVERVIEW
27.15.2 REVENUE ANALYSIS
27.15.3 GEOGRAPHIC PRESENCE
27.15.4 PRODUCT PORTFOLIO
27.15.5 RECENT DEVELOPEMENTS
27.16 IMMUNOTEK BIO CENTERS
27.16.1 COMPANY OVERVIEW
27.16.2 REVENUE ANALYSIS
27.16.3 GEOGRAPHIC PRESENCE
27.16.4 PRODUCT PORTFOLIO
27.16.5 RECENT DEVELOPEMENTS
27.17 KAMADA PHARMACEUTICALS
27.17.1 COMPANY OVERVIEW
27.17.2 REVENUE ANALYSIS
27.17.3 GEOGRAPHIC PRESENCE
27.17.4 PRODUCT PORTFOLIO
27.17.5 RECENT DEVELOPEMENTS
27.18 PROMETIC PLASMA RESOURCES
27.18.1 COMPANY OVERVIEW
27.18.2 REVENUE ANALYSIS
27.18.3 GEOGRAPHIC PRESENCE
27.18.4 PRODUCT PORTFOLIO
27.18.5 RECENT DEVELOPEMENTS
27.19 PLASMA INDUCTION (INDIA) PVT LTD.
27.19.1 COMPANY OVERVIEW
27.19.2 REVENUE ANALYSIS
27.19.3 GEOGRAPHIC PRESENCE
27.19.4 PRODUCT PORTFOLIO
27.19.5 RECENT DEVELOPEMENTS
27.2 HAEMONETICS CORPORATION
27.20.1 COMPANY OVERVIEW
27.20.2 REVENUE ANALYSIS
27.20.3 GEOGRAPHIC PRESENCE
27.20.4 PRODUCT PORTFOLIO
27.20.5 RECENT DEVELOPEMENTS
27.21 CHINA BIOLOGIC PRODUCTS
27.21.1 COMPANY OVERVIEW
27.21.2 REVENUE ANALYSIS
27.21.3 GEOGRAPHIC PRESENCE
27.21.4 PRODUCT PORTFOLIO
27.22 KM BIOLOGICS
27.22.1 COMPANY OVERVIEW
27.22.2 REVENUE ANALYSIS
27.22.3 GEOGRAPHIC PRESENCE
27.22.4 PRODUCT PORTFOLIO
27.23 SHANXI KANGBAO BIOLOGICAL PRODUCTS CO., LTD
27.23.1 COMPANY OVERVIEW
27.23.2 REVENUE ANALYSIS
27.23.3 GEOGRAPHIC PRESENCE
27.23.4 PRODUCT PORTFOLIO
27.24 SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO., LTD
27.24.1 COMPANY OVERVIEW
27.24.2 REVENUE ANALYSIS
27.24.3 GEOGRAPHIC PRESENCE
27.24.4 PRODUCT PORTFOLIO
27.25 ADMA BIOLOGICS, INC.
27.25.1 COMPANY OVERVIEW
27.25.2 REVENUE ANALYSIS
27.25.3 GEOGRAPHIC PRESENCE
27.25.4 PRODUCT PORTFOLIO
27.25.5 RECENT DEVELOPEMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
28 RELATED REPORTS
29 CONCLUSION
30 QUESTIONNAIRE
31 ABOUT DATA BRIDGE MARKET RESEARCH
